Navigation Links
Palatin Technologies Announces Option for License to Bremelanotide in Europe
Date:11/13/2013

CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union. 

Palatin received a $1.0 million, non-refundable option fee under the option agreement.  Subject to certain contingencies, if not exercised the option expires in the first calendar quarter of 2014. 

The option agreement is with a European specialty pharmaceutical company with pharmaceutical manufacturing, research and development, and sales and marketing capabilities.  As part of the option agreement, the parties are seeking regulatory advice from the European Medicines Agency on phase 3 clinical data required for approval of bremelanotide for female sexual dysfunction in the European Union.

"We believe that the two largest potential markets for bremelanotide are the United States and the European Union," stated Carl Spana, Ph.D., President and CEO of Palatin.  "Based on a number of factors, it may be most effective to have separate partners for the United States and for the European Union.  We are pleased with the relationship with our potential European partner, which has extensive European regulatory experience and has been instrumental in preparing for our meeting with the European Medicines Agency.  We are optimistic we will be able to successfully conclude a definitive agreement with them on European commercialization of bremelanotide for female sexual dysfunction.  We are also in active discussions with multiple pharm
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
2. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
3. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
7. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
8. Patient Safety Technologies Reports Third Quarter 2013 Results
9. BioSpecifics Technologies Corp. Reports Third Quarter 2013 Financial Results
10. Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
11. Study Assesses New Tools, Technologies, and Approaches for Understanding and Communicating with Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The global ... of products, methods, applications, end users, and geographies. ... in the microbial identification market. This favorable growth ... (per test) and the time required for microbial ... technological advancements. Furthermore, genotypic methods have high applications ...
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
(Date:7/29/2014)... 29, 2014  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $515.2 million, or ... as detailed in Table 4, was $1.23 for the ... positioned to serve our clients with scale, alignment and innovative ... the health outcomes of our members," stated George Paz, chairman ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... 2011  TransTech Medical Solutions ( http://www.transtechmedical.com ), today announced ... for Transcription Services in the 2011 Top ... report.  TransTech has previously been ranked #3 in ... the highest overall performance score and 100% of the ...
... 2011  Today, the Consumer Healthcare Products Association (CHPA), announced Tammy ... Five Moms campaign to raise awareness of teen ... two teenage boys and a high school math teacher from ... dangers of substance abuse. Millions of Americans ...
Cached Medicine Technology:TransTech Medical Solutions Ranked #1 by KLAS for 2011 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:7/29/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer ... bridal gowns . Aside from this, it has announced that ... 68 percent off. All of its old and new clients ... sales representative says excitedly, “We are pleased to release the ... there are a lot of amazing items. It is true ...
(Date:7/29/2014)... City, MO (PRWEB) July 30, 2014 ... practices have recently been awarded the Patient-Centered Medical ... by the National Committee for Quality Assurance. Only ... achieved NCQA Level I, Level 2, or Level ... who participate in Patient-Centered Medical Home report faster ...
(Date:7/29/2014)... St. Petersburg, FL (PRWEB) July 30, 2014 Phytceramides ... explains how and why in her new book. , Today is ... Phytoceramides: Anti Aging At Its Best . The book is ... larger skin care book, but felt that Phytoceramides were ... sense to bring out this focused book now," says Kathy Heshelow, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 1Heart ... senior communities with focus on Brain Fitness Education ... in Ventura. Brain Fitness Program Director Tee Barr ... Aegis Memory Care unit and the Assisted Living ... Aegis Life Enrichment Director Christy Rozsa and Aegis ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
Breaking Medicine News(10 mins):Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Amilpar (Bovespa: AMIL3;,Bloomberg: AMIL3 BZ and APAR < GO >; ... results for the third quarter,of 2009. , ... thousand at the end of September 2009,2.7% up on 3Q08 and ... Operating Revenues totaled R$ 1,237.1 million in 3Q09, 8.4% up,year-on-year and ...
... 11 In its continuing initiatives around Doing What,s Right, ... as part of its involvement in the Clinton Global Initiative ... brings world leaders from a variety of backgrounds together to ... some of the world,s most pressing challenges. , SC ...
... sick, but elderly more likely to die , WEDNESDAY, Nov. 11 ... finds that while babies and people under the age of 40 ... death rates. , The research, published online Nov. 11 in ... in the Mexican Institute for Social Security network, who became sick ...
... published reports , WEDNESDAY, Nov. 11 (HealthDay News) -- ... company suggests that clinical data was manipulated to make ... than it actually was, thereby increasing possibilities for its ... means we,re not seeing the full picture, and the ...
... ... also desperate pioneers whose drug use had gotten the better of them every ... whether an epilepsy drug could reduce their use of cocaine. In the end, ... the final three weeks of the study with no signs of cocaine use ...
... 11 An article running in the new issue ... , "Silent Epidemic of Viral Hepatitis May Lead to ... for Congress to act on new bipartisan legislation, HR ... research, and medical management referral program for chronic hepatitis ...
Cached Medicine News:Health News:Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09 2Health News:SC Johnson Makes Commitment to Clinton Global Initiative 2Health News:SC Johnson Makes Commitment to Clinton Global Initiative 3Health News:Older People at Greater Risk of Swine Flu Death 2Health News:Trial Data on Anti-Seizure Drug Might Have Been Manipulated: Report 2Health News:Trial Data on Anti-Seizure Drug Might Have Been Manipulated: Report 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:NVHR: New JAMA Article Underscores Urgent Need for Congress to Act on Viral Hepatitis Detection, Management Funding 2
...
...
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Medicine Products: